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Abstract
Background: Pilocytic astrocytoma is the most common type of brain tumor in the pediatric population, with a
generally favorable prognosis, although recurrences or leptomeningeal dissemination are sometimes also observed.
For tumors originating in the supra-or infratentorial location, a different molecular background was suggested, but
plausible correlations between the transcriptional profile and radiological features and/or clinical course are still
undefined. The purpose of this study was to identify gene expression profiles related to the most frequent locations
of this tumor, subtypes based on various radiological features, and the clinical pattern of the disease.
Methods: Eighty six children (55 males and 31 females) with histologically verified pilocytic astrocytoma were
included in this study. Their age at the time of diagnosis ranged from fourteen months to seventeen years, with a
mean age of seven years. There were 40 cerebellar, 23 optic tract/hypothalamic, 21 cerebral hemispheric, and two
brainstem tumors. According to the radiological features presented on MRI, all cases were divided into four
subtypes: cystic tumor with a non-enhancing cyst wall; cystic tumor with an enhancing cyst wall; solid tumor with
central necrosis; and solid or mainly solid tumor. In 81 cases primary surgical resection was the only and curative
treatment, and in five cases progression of the disease was observed. In 47 cases the analysis was done by using
high density oligonucleotide microarrays (Affymetrix HG-U133 Plus 2.0) with subsequent bioinformatic analyses and
confirmation of the results by independent RT-qPCR (on 39 samples).
Results: Bioinformatic analyses showed that the gene expression profile of pilocytic astrocytoma is highly dependent
on the tumor location. The most prominent differences were noted for IRX2, PAX3, CXCL14, LHX2, SIX6, CNTN1 and SIX1
genes expression even within different compartments of the supratentorial region. Analysis of the genes potentially
associated with radiological features showed much weaker transcriptome differences. Single genes showed association
with the tendency to progression.
Conclusions: Here we have shown that pilocytic astrocytomas of three different locations can be precisely differentiated
on the basis of their gene expression level, but their transcriptional profiles does not strongly reflect the radiological
appearance of the tumor or the course of the disease.
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Background
Pilocytic astrocytoma (PA) is the most common type of
brain tumor in the pediatric population, comprising ap-
proximately 25 % of all primary tumors, with the most fre-
quent occurrence taking place between 5–10 years of age.
Fortunately this tumor has a generally good outcome, how-
ever recurrences or leptomeningeal dissemination are also
sometimes observed. PAs can affect various anatomical
structures, but there are three most common locations:
cerebellum, optic tract with hypothalamus, and cerebral
hemispheres. Those tumors are mainly sporadic, except for
cases occurring in patients with neurofibromatosis type 1
and, less frequently, with Frasier and Noonan syndromes
[1–3]. Molecularly, pilocytic astrocytoma is characterized
by a relatively small number of chromosomal abnormalities
with the most common alteration located at chromosome
7q34 comprising the BRAF oncogene [4, 5]. In the high-
throughput analysis era, limited reports of this type of
tumor were made using expression profiling. The presup-
position concerning the molecular heterogeneity of pilocy-
tic astrocytomas was defined previously by Wong et al. as
the result of unsupervised hierarchical clustering. Without
inference from a clinical outcome, they identified two sub-
groups of tumors. Such results could be a consequence of
including two cases of subtotally resected tumors and, more
importantly, the more aggressive variant of astrocytoma
with pilomyxoid features [6]. Later, an assumption describ-
ing different expression profiles for PAs of various locations
was given by Sharma et al., who showed the LHX2 gene ex-
pression to be connected with supratentorial location [7]. A
following analysis made by Tchoghandjian et al. showed up-
regulation of LHX2 together with SIX6 in tumors originated
from the hypothalamo-chiasmatic region [8]. At the same
time, MATN2 and ALDH1L1 genes were assumed to be
connected with plausible PAs progression despite total sur-
gical resection [9, 10]. Children affected by this tumor
usually have a good prognosis, although in some cases re-
currence or leptomeningeal dissemination may be observed
[11–14]. Thus there is an ongoing need to search for
molecular markers influencing the clinical behavior of this
tumor. On the basis of observations made to date we
verified the hypothesis that the location of pilocytic
astrocytomas is the major cause of their genomic differ-
ences, and tried to find genes connected with patient
outcome and tumor appearance. The aim of this study
was to identify gene expression profiles related to the
most frequent locations, radiological features, and the
clinical course of the disease in a representative group
of Polish children with PAs.
Methods
Patient samples
Eighty-six children with pilocytic astrocytoma who were
operated on at the Department of Neurosurgery, Polish
Mother’s Memorial Hospital, Research Institute in Lodz
were included in this study. The group was comprised of
55 males and 31 females. The median age of patients at the
time of diagnosis was 7 years (ranging from 14 months to
17 years). There were 40 cerebellar, 23 optic tract and hypo-
thalamic, 21 cerebral hemispheric, and 2 brainstem tumors
(Fig. 1). All specimens were diagnosed at the Department
of Molecular Pathology and Neuropathology, Medical
University of Lodz, according to the WHO criteria [1].
In all patients, preoperative MRI scans with and without
contrast administration were obtained. For assessing the
radiological features of tumors, we adopted the classifica-
tion of radiological subtypes of PA proposed by Pencalet et
al., commonly used in analyses of this tumor [15, 16].
According to the radiological features presented on
MRI, all tumors were divided into four subtypes: cystic
with a non-enhancing cyst wall, cystic with an enhan-
cing cyst wall, solid with central necrosis, and solid or
mainly solid tumors (Fig. 2).
In 81 cases primary surgical resection was the only
and curative treatment, while in five cases progression
of the disease, requiring additional treatment, was
noted. In two cases clinical manifestation of neuro-
fibromatosis type 1 (NF1) was observed. The clinical
data of patients included in this study are presented in
Table 1. All samples were collected using the protocols
approved by the Bioethics Medical University Commit-
tee (Approval No. RNN/154/06/KE).
Written informed parental consent was obtained from
all patients under 16 (75 patients). In eleven older pa-
tients the participants gave their own consent according
to the Polish law. All data were processed and stored in
compliance with the Helsinki Declaration.
RNA isolation
Total RNA was extracted from the snap-frozen tumor
tissues stored at–80 °C after excision, using the acid
phenol-guanidinum extraction method, purified using
commercially available sets (RNeasy Mini Kit, Qiagen)
and treated with DNAase (Qiagen) [17]. In order to obtain
a high amount of RNA, macrodissection was used in all
cases. Specimens were visually assessed by the pathologist
to confirm that at least 50 % of tumor cells within the
sample and areas with highest content of neoplastic tissue
were used for direct RNA extraction. The quantity of
RNA was measured using the NanoDrop 1000 (Thermo
Scientific). RNA samples’ quality was analysed using 2000
Bioanalyzer (Agilent Technologies), and after capillary
electrophoresis the RNA integrity number (RIN) was gen-
erated by the software for each specimen.
cRNA synthesis and hybridization
250 ng RNA of each sample selected for array analysis
(50 cases) was used for cDNA and subsequent cRNA
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synthesis (GeneChip® 3′ IVT Expression Kit, Affymetrix).
The amplified and biotinylated complementary RNA
(cRNA) was purified and fragmented using heat and
Mg2+, and then underwent hybridization (45 °C,
16 hours) with GeneChip Human Genome U133 Plus 2.0
Array (Affymetrix), followed by array staining (Streptavi-
din, Alexa Fluor 610-R-phycoerythrin conjugate, Molecu-
lar Probes). All procedures were performed according to
the manufacturer’s instructions (Affymetrix). Arrays were
scanned using the GeneChip Scanner 3000 (Affymetrix).
Microarray analysis
Quality control of microarray data was carried out
according to standard protocols, based on R/Bioconduc-
tor packages (ver. 2.3.5). Data were pre-processed using
the GC-Robust Multi-array Average (GC-RMA) proced-
ure, Normalized Unscaled Standard Error (NUSE) and
Relative Log Expression (RLE) measures were calculated
to verify the technical homogeneity of the dataset. On
the basis of quality control, 47 out of 50 microarrays
were then classified to the bioinformatic analyses.
Transcripts showing minimal variation of expression
across the set of arrays were excluded from the analysis.
Genes with expression differed by at least 1.5 times from
the median in at least 10 % of the arrays, with variance
significantly larger than the median variance (p ≤ 0.01)
retained. For the selection of genes’ differentiating sub-
groups, the Welch t-test with false discovery rate (FDR)
estimation was used. A global test was applied to test
whether the expression profiles differed between the
classes by permuting the labels of which arrays corre-
sponded to which classes. Biological relevance and
contribution in cellular processes of obtained sets was
analyzed by Gene Ontology classification on the basis
of the Gene Ontology Consortium database (http://
www.geneontology.org). For selected genes the gene set
enrichment analysis, with curated and motif gene set
collections, was performed to analyze the signaling
pathways (Molecular Signatures Database v. 3.0, http://
www.broadinstitute.org/gsea/msigdb/index.jsp). These
analyses were performed using Kolmogorov-Smirnov,
the Least Squares test, and the Gene Set Analysis
method (p ≤ 0.001). Statistical analysis was carried out
Fig. 1 Location of pilocytic astrocytoma. a cerebral hemispheric tumor. b optic tract and hypothalamic tumor. c cerebellar tumor. d brainstem
tumor. MRI scans after contrast administration
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by BRB-Array Tools (ver. 4.1.0, http://linus.nci.nih.gov/
BRB-ArrayTools.html, developed by Dr R. Simon and
BRB-Array Tools Development Team) and R/Biocondu
ctor packages (http://www.bioconductor.org).
Validation of the microarray data
Correlation analysis of RT-qPCR and microarray expres-
sion values were carried out for 39 independent samples
equally diversified according to the three tumor locations:
cerebral hemispheric tumors (M1), optic tract and hypo-
thalamic tumors (M2), cerebellar tumors (M3). TaqMan®
Gene Expression Assays by TaqMan® real time PCR with
TaqMan® Universal PCR Master Mix (Applied Biosystems,
UK) was used following the manufacturer’s instructions
on a Rotor Gene 6000 instrument (Qiagene-Corbett Life
Science, Sydney, Australia) for selected genes (Additional
file 1: Table S1). The PCR reactions for each assay were
run in triplicate and the results were averaged. The nor-
malized relative expression level of the genes of interest
was calculated according to the method described by Pfaffl
and Vandesompele et al., with GAPDH used as a reference
gene [18, 19]. Statistical comparison of three subgroups
was made on the basis of the Kruskal-Wallis nonparamet-
ric test, with post hoc pairwise comparisons using the
Dwass-Steel-Critchlow-Fligner test. Statistical significance
was assumed for p ≤ 0.05.
Results
We performed bioinformatic analysis of the global gene
expression of 47 childhood pilocytic astrocytoma with re-
spect to the selected clinical features. After pre-processing
of the data 21,910 probesets showed significant variance
and were further analysed. For the purposes of bioinfor-
matic analysis, all analyzed samples were divided, on the
basis of pivotal clinical data, into eight subgroups: cerebral
hemispheric tumors (M1); optic tract and hypothalamic
tumors (M2); cystic cerebellar tumors with an non-
enhanced cyst (M3R1); cystic cerebellar tumors with an
enhanced cyst (M3R2); solid cerebellar tumors with cen-
tral necrosis (M3R3); solid or mainly solid cerebellar
tumors (M3R4); tumors linked to the neurofibromatosis
type 1 (NF1); and progressive tumors (P2).
During the comparison of these eight subgroups using
the parametric Welch t-test and post hoc class comparison
Fig. 2 Radiological type of pilocytic astrocytoma. a cystic tumor with an enhancing cyst wall, R1. b cystic tumor with a non-enhancing cyst wall,
R2. c solid tumor with central necrosis, R3. d solid or mainly solid tumor, R4. MRI scans after contrast administration
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test, we found 345 probesets with significantly changed
expression (p < 0.001). The observed differences were
also strongly significant in the global test (p < 0.007)
(Additional file 2: Table S2).
The evaluation of biological processes represented
within the selected genes was done on the basis of the
gene ontology over-representation analysis. The most sig-
nificantly represented ontology classes were connected
with neuronal cells building proteins, adhesion molecules,
cell junctions, and hormone and neuropeptides activity
(Table 2). Within genes with significantly changed expres-
sion, there were some that connected with transcriptional
processes and acting during embryogenesis and central
nervous system differentiation.
The analysis of selected genes’ contribution in the sig-
naling pathways revealed changed regulation of 77 within
2131 curated gene sets, and 14 within 179 motif gene sets.
The highest statistical significance was obtained for genes
functionally connected with immune response pathways,
pathways engaged in silencing suppressors during histone
methylation and activation of the NFkB pathway. Interest-
ing group consisted of targets for miR324-5p, miR432,
miR299-3P, miR486 and miR499 and genes located near
promoter regions of NR6A1, POU3F2, CUTL1, PAX8 and
AHR transcription factors (Table 3).
In the next step we analyzed the expression values of
genes differentiating clinical subgroups of PA. Genes
with highest amplitude were chosen for hierarchical
clustering of samples (Fig. 3a). On the basis of such ana-
lysis we obtained three distinct clusters showing almost
perfect classification of samples, which revealed that the
main source of variability is related to the location of the
tumors. The cerebellar tumors consist of a homogenic
cluster, while the supratentorial samples showed single
outlier specimens (Fig. 3b). Within tumors of optic tract
and hypothalamus there was also a sample of brain stem
PA, which presented a low correlation of gene expres-
sion with the supratentorial cases (r = 0,4). This sample
was excluded from statistical analyses because of its low
RNA quality, and as a consequence both cases of PA
located within the brain stem were used only during
data visualization.
Bioinformatic analysis of our dataset revealed that 32
probesets showed different expression pattern according
to radiological subclasses (p < 0.005). Unfortunately these
genes demonstrated weak transcriptome differences
(Fig. 4a), with borderline significance in the global test of
association (p = 0,88). Hierarchical clustering and PCA
analyses taking into account the radiological features of
tumors did not show a specific gene expression signature
correlated with the radiological features of analyzed PA
(Fig. 4b, c).
Here we verified the hypothesis that the location of
PAs is the major cause of their genomic differences.
Analyses of three main anatomical subclasses (M1, M2,
M3) using the parametric Welch t-test were very prom-
inent and revealed statistically significant differences for
862 probesets based on the false discovery rate (FDR
adjusted p-value of 0.001).
In the global test the differences were also strongly
significant (p < 0.001). The comparisons of pairs (M1vsM3;
M2vsM3; M1vsM2) using the post hoc test (BRB Array-
Tools) revealed that the majority of genes showed different
expression for the M2vsM3 and M1vsM3 (847 and 323
genes respectively), while 105 genes showed differences
both for M1vsM3 and M2vsM3 tumors. The most




Male 55 64 %
Female 31 36 %
Age
0-9 years 53 62 %
10-17 years 33 38 %
Histopathology
Pilocytic astrocytoma 86 100 %
Location
Cerebellum 40 47 %
Optic tracts/Hypothalamus 23 27 %
Hemisphere 21 24 %
Brainstem 2 2 %
Radiological appearance
Solid or mainly solid 43 50 %
Cystic/Enhanced 24 28 %
Cystic/Non enhanced 10 12 %
Largely necrotic 9 10 %
Extent of resection
Gross total 63 73 %
Partial 23 27 %
Clinical course and current patient status
Cured 81 94 %
Alive 80 99 %
Dead 1 1 %
Progressive 5 6 %
Alive 4 99 %
Dead 1 1 %
Genetic conditions
NF1 excluded 84 98 %
NF1 confirmed 2 2 %
Total 86 100 %
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Table 2 Gene ontology (GO) analysis of genes selected from transcripts differentiating the clinical subgroups of pilocytic
astrocytomas







GO:0031225 Anchored to membrane 6 1.66 3.62
GO:0005925 Focal adhesion 6 1.72 3.48
GO:0009897 External side of plasma membrane 6 1.77 3.4
GO:0005924 Cell-substrate adherens junction 6 1.77 3.4
GO:0031253 Cell projection membrane 5 1.52 3.28
GO:0005912 Adherens junction 9 2.83 3.19
GO:0030055 Cell-substrate junction 6 1.92 3.12
GO:0043235 Receptor complex 5 1.74 2.87
GO:0044297 Cell body 6 2.27 2.64
GO:0043025 Neuronal cell body 6 2.27 2.64
Molecular functions
GO:0019842 Vitamin binding 6 1.84 3.26
GO:0019900 Kinase binding 9 2.9 3.1
GO:0019901 Protein kinase binding 7 2.3 3.05
GO:0003714 Transcription corepressor activity 6 2.25 2.66
GO:0008234 Cysteine-type peptidase activity 6 2.34 2.56
GO:0042277 Peptide binding 5 2.3 2.18
Biological processes
GO:0032677 Regulation of interleukin-8 production 6 0.37 16.38
GO:0032637 Interleukin-8 production 6 0.4 15.12
GO:0003081 Regulation of systemic arterial blood pressure by renin-angiotensin 5 0.34 14.89
GO:0001990 Regulation of systemic arterial blood pressure by hormone 5 0.43 11.7
GO:0002221 Pattern recognition receptor signaling pathway 7 0.82 8.49
GO:0003044 Regulation of systemic arterial blood pressure mediated by a chemical signal 5 0.61 8.19
GO:0002758 Innate immune response-activating signal transduction 7 0.89 7.91
GO:0002218 Activation of innate immune response 7 0.89 7.91
GO:0003073 Regulation of systemic arterial blood pressure 5 0.64 7.8
GO:0050886 Endocrine process 5 0.73 6.83
GO:0021953 Central nervous system neuron differentiation 5 0.76 6.55
GO:0050731 Positive regulation of peptidyl-tyrosine phosphorylation 6 0.95 6.34
GO:0050729 Positive regulation of inflammatory response 5 0.82 6.07
GO:0002768 Immune response-regulating cell surface receptor signaling pathway 7 1.19 5.88
GO:0050864 Regulation of B cell activation 6 1.07 5.62
GO:0050671 Positive regulation of lymphocyte proliferation 6 1.07 5.62
GO:0070665 Positive regulation of leukocyte proliferation 6 1.1 5.46
GO:0048839 Inner ear development 8 1.47 5.46
GO:0032946 Positive regulation of mononuclear cell proliferation 6 1.1 5.46
GO:0002429 Immune response-activating cell surface receptor signaling pathway 6 1.13 5.31
GO:0050730 Regulation of peptidyl-tyrosine phosphorylation 7 1.47 4.78
GO:0050670 Regulation of lymphocyte proliferation 8 1.71 4.68
GO:0070663 Regulation of leukocyte proliferation 8 1.74 4.6
GO:0032944 Regulation of mononuclear cell proliferation 8 1.74 4.6
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Table 2 Gene ontology (GO) analysis of genes selected from transcripts differentiating the clinical subgroups of pilocytic
astrocytomas (Continued)
GO:0042129 Regulation of T cell proliferation 5 1.13 4.43
GO:0032103 Positive regulation of response to external stimulus 7 1.62 4.33
GO:0002706 Regulation of lymphocyte mediated immunity 5 1.19 4.2
GO:0050727 Regulation of inflammatory response 6 1.47 4.1
GO:0043583 Ear development 8 1.98 4.03
GO:0009310 Amine catabolic process 8 1.98 4.03
GO:0090047 Positive regulation of transcription regulator activity 5 1.31 3.81
GO:0051091 Positive regulation of transcription factor activity 5 1.31 3.81
GO:0008217 Pegulation of blood pressure 7 1.86 3.76
GO:0051606 Detection of stimulus 6 1.65 3.64
GO:0021537 Telencephalon development 8 2.2 3.64
GO:0009064 Glutamine family amino acid metabolic process 5 1.37 3.64
GO:0002822 Regulation of adaptive immune response based on somatic recombination of immune
receptors built from immunoglobulin superfamily domains
5 1.37 3.64
GO:0002703 Regulation of leukocyte mediated immunity 5 1.37 3.64
GO:0050870 Positive regulation of T cell activation 7 1.95 3.58
GO:0002819 Regulation of adaptive immune response 5 1.4 3.56
GO:0043388 Positive regulation of DNA binding 5 1.43 3.49
GO:0051099 Positive regulation of binding 6 1.74 3.45
GO:0009063 Cellular amino acid catabolic process 6 1.74 3.45
GO:0043410 Positive regulation of MAPKKK cascade 5 1.5 3.34
GO:0090046 Regulation of transcription regulator activity 8 2.47 3.24
GO:0051090 Regulation of transcription factor activity 8 2.47 3.24
GO:0048562 Embryonic organ morphogenesis 8 2.53 3.16
GO:0046651 Lymphocyte proliferation 8 2.53 3.16
GO:0042113 B cell activation 8 2.53 3.16
GO:0018108 Peptidyl-tyrosine phosphorylation 8 2.53 3.16
GO:0045927 Positive regulation of growth 5 1.62 3.09
GO:0018212 Peptidyl-tyrosine modification 8 2.59 3.08
GO:0070661 Leukocyte proliferation 8 2.62 3.05
GO:0032943 Mononuclear cell proliferation 8 2.62 3.05
GO:0007187 G-protein signaling, coupled to cyclic nucleotide second messenger 5 1.65 3.03
GO:0002237 Response to molecule of bacterial origin 6 1.98 3.02
GO:0046395 Carboxylic acid catabolic process 8 2.66 3.01
GO:0016054 Organic acid catabolic process 8 2.66 3.01
GO:0042098 T cell proliferation 5 1.68 2.98
GO:0042445 Hormone metabolic process 7 2.38 2.94
GO:0019935 Cyclic-nucleotide-mediated signaling 6 2.04 2.93
GO:0009952 Anterior/posterior pattern formation 6 2.08 2.89
GO:0010001 Glial cell differentiation 5 1.77 2.82
GO:0009266 Response to temperature stimulus 5 1.77 2.82
GO:0071375 Cellular response to peptide hormone stimulus 6 2.14 2.81
GO:0030217 T cell differentiation 9 3.27 2.76
GO:0045664 Regulation of neuron differentiation 9 3.33 2.71
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similarities (24 strongly differentiating genes) were noted
for two analyzed supratentorial subgroups (Table 4, Fig. 3d,
Additional file 3: Table S3 and Additional file 4: Table S4).
These comparisons were also repeated with more restricted
statistical criteria using the Benjamini-Hochberg multiple
comparisons correction, with the criterion of FDR < 1 %.
After comparison of the M3 and combined M1 and M2
subgroups, a list of 348 probesets was obtained. The prob-
ability of proper classification of tumors on the basis of
gene expression profile reached a range of 80 % accuracy.
In order to exclude the potential influence of other
clinical variables on the obtained results, additional ana-
lysis was also performed for infratentorial cases, which
included all four radiological types of PA. This approach
confirmed our observations.
Our analyses of the transcriptome profile of five cases
with progressive disease did not show any correlation
with a worse outcome. Only five genes (SIX3, RGS8,
FAM82, KIF9, WDR63) reached statistical significance
(p = 0.001) when the univariate model was used, but the
global test revealed that this association did not meet
the criteria of statistical significance (p = 0.83) (Fig. 5a).
Cases with neurofibromatosis type 1 had no connection
with expression profile.
In the final stage of analysis we applied an unsuper-
vised method (Principal Component Analysis, PCA) to
Table 2 Gene ontology (GO) analysis of genes selected from transcripts differentiating the clinical subgroups of pilocytic
astrocytomas (Continued)
GO:0050863 Regulation of T cell activation 8 2.99 2.67
GO:0001934 Positive regulation of protein amino acid phosphorylation 6 2.29 2.62
GO:0051222 Positive regulation of protein transport 5 1.95 2.56
GO:0002460 Adaptive immune response based on somatic recombination of immune receptors
built from immunoglobulin superfamily domains
7 2.87 2.44
GO:0043408 Regulation of MAPKKK cascade 7 2.9 2.41
GO:0042327 Positive regulation of phosphorylation 6 2.5 2.4
GO:0034097 Response to cytokine stimulus 6 2.5 2.4
GO:0002250 Adaptive immune response 7 2.93 2.39
GO:0002449 Lymphocyte mediated immunity 6 2.53 2.37
GO:0050953 Sensory perception of light stimulus 7 3.02 2.32
GO:0007601 Visual perception 7 3.02 2.32
GO:0045937 Positive regulation of phosphate metabolic process 6 2.59 2.31
GO:0042063 Gliogenesis 5 2.17 2.31
GO:0010562 Positive regulation of phosphorus metabolic process 6 2.59 2.31
GO:0007411 Axon guidance 5 2.17 2.31
GO:0043010 Camera-type eye development 5 2.2 2.28
GO:0009617 Response to bacterium 8 3.51 2.28
GO:0002697 Regulation of immune effector process 5 2.2 2.28
GO:0032870 Cellular response to hormone stimulus 8 3.54 2.26
GO:0071495 Cellular response to endogenous stimulus 8 3.57 2.24
GO:0030855 Epithelial cell differentiation 5 2.23 2.24
GO:0030258 Lipid modification 5 2.23 2.24
GO:0043122 Regulation of I-kappaB kinase/NF-kappaB cascade 6 2.78 2.16
GO:0008643 Carbohydrate transport 5 2.32 2.16
GO:0048568 Embryonic organ development 8 3.72 2.15
GO:0051239 Regulation of multicellular organismal process 72 33.82 2.13
GO:0008624 Induction of apoptosis by extracellular signals 5 2.38 2.1
GO:0007399 Nervous system development 84 41.36 2.03
GO:0002376 Immune system process 80 39.37 2.03
GO:0003002 Regionalization 8 3.97 2.02
The number of genes changed in each category was compared with the number of expected occurrences. Only GO classes and parent classes with at least five
observations in the selected subset and with an ’observed vs. expected’ ratio of at least two were shown
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determine the sources of variability in our group of
samples according to the clinical data, and that analysis
also indicated that the gene expression profile of pilocy-
ticastrocytomas highly depends on the tumor’s location
(p = 0.001), but not on other clinical features (Figs. 3c,
4c and 5b).
As the analysis of the most important determinants of
gene expression (including location and radiological ap-
pearance) include the potential for multivariate associa-
tions, we carried out a two-way analysis of variance. In
this multivariate approach two variables were taken into
account (location: supratentorial vs infratentorial, i.e.
M1 +M2 vs M3 +M4, and radiology: cystic vs solid, i.e.
R1 + R2 vs R3 + R4). In the multivariate analysis only
location seemed to be associated with gene expression
(702 probesets with non-corrected p-value < 0.001, 1007
probesets with FDR < 10 %), while radiological appear-
ance was almost without influence on gene expression
(5 probesets with non-corrected p < 0.001, no probesets
with FDR below 10 %).
During our analysis the most prominent differences
connected with the location of the tumor were noted for
the IRX2, PAX3, CXCL14, LHX2, SIX6, CNTN1 and SIX1
genes. For all these genes we performed validation results
by independent RT-qPCR on 39 cases of PA, which con-
firmed the data obtained during microarray analysis with
similar expression differences. For the PAX3, LHX2,
CNCT1 and CXCL14 genes we obtained results which
converged with the microarray results and these discrimi-
nants were the best to differentiate M1 and M2 from M3
tumors. For PAX3, LHX2, IRX2 and CNTN1 genes similar
as in microarray analysis, the major expression differences
for M1/M2 and M3 tumors was showen. The gene with a
statistically significant level of expression for all three sub-
groups of tumors was SIX1 (Fig. 6).
The data discussed in this publication have been depos-
ited in the NCBI’s Gene Expression Omnibus and are
accessible through the GEO Series accession number
GSE73066 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cg
i?acc=GSE73066) [20].





KONDO_PROSTATE_CANCER_HCP_WITH_H3K27ME3 100 0.00001 0.00001 <0.005
LI_CISPLATIN_RESISTANCE_UP 66 0.00001 0.00019 <0.005
REACTOME_ACTIVATED_TLR4_SIGNALLING 25 0.00001 0.00001 <0.005
REACTOME_TOLL_LIKE_RECEPTOR_4_CASCADE 28 0.00001 0.00001 <0.005
SHARMA_PILOCYTIC_ASTROCYTOMA_LOCATION_DN 7 0.00001 0.00001 <0.005
SHARMA_PILOCYTIC_ASTROCYTOMA_LOCATION_UP 31 0.00001 0.00001 <0.005
WATANABE_COLON_CANCER_MSI_VS_MSS_DN 96 0.00001 0.00041 <0.005
ZHAN_MULTIPLE_MYELOMA_PR_DN 69 0.00001 0.00001 <0.005
BIOCARTA_DC_PATHWAY 13 0.00023 0.00079 <0.005
CGGTGTG, MIR-220 8 0.00001 0.09215 <0.005
V$GNCF_01 93 0.00002 0.00239 0.04
GGGATGC, MIR-324-5P 72 0.00003 0.01085 <0.005
CCATCCA, MIR-432 64 0.00006 0.00044 0.015
V$POU3F2_01 94 0.00006 0.02333 0.025
CCANNAGRKGGC_UNKNOWN 89 0.00017 0.00001 0.035
V$CDPCR3_01 39 0.00028 0.02874 0.065
CCCACAT,MIR-299-3P 72 0.00034 0.08243 0.07
V$MYOGNF1_01 57 0.00045 0.01553 0.045
CTGYNNCTYTAA_UNKNOWN 73 0.00055 0.00747 0.09
GTACAGG, MIR-486 72 0.00056 0.00176 0.01
V$PAX8_01 49 0.00058 0.0018 <0.005
V$AHR_01 86 0.00068 0.05371 0.16
CCAATNNSNNNGCG_UNKNOWN 65 0.00407 0.22226 <0.005
AGTCTTA, MIR-499 99 0.02398 0.00033 0.22
V$MEF2_04 24 0.03997 0.01638 <0.005
Three independent tests: LS, KS permutation test, and Efron-Tibshirani’s GSA maxmean test were applied to select significantly affected gene classes
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Discussion
In the current study we performed expression analysis of
PAs diversified according to the main clinical discrimi-
nants, from which the tumor location was the most
important. We also tried to verify if and how the transcrip-
tional profile is connected with the radiological appearance
of the tumor. Moreover we attempted to identify the
expression profiles related to the clinical course of the
disease.
Unsupervised clustering analysis revealed differences
between PAs located in three anatomical regions,
which was also well confirmed by decomposition into
principal components (Fig. 3b, c). The specific tran-
scriptional profile for hemispheric tumors was mainly
characterized by upregulation of FOXG1, NEDD4L,
L1CAM and CXCL14 genes. The FOXG1 and NEDD4L
have a functional connection with the TGF-beta
signaling pathway which is involved in cells’ prolifera-
tion and differentiation irregularities noted in other
brain tumors, including gliomas, medulloblastomas
and supratentorial ependymomas [21–23]. For the fol-
lowing L1CAM, acting during brain development and
having an unknowable role in the adult nervous sys-
tem, the correlation with tumor grade in several other
solid human cancers was noted [22, 24]. In turn,
expression of CXCL14 chemokine with enigmatic
physiological function is connected with the tendency
of tumor infiltration described on the basis of in vitro
studies [25, 26]. Taken together, these genes are closely
related not only to brain development but also to brain
tumor growth and expansion. In this subgroup we also
found the moderate overexpression of the LHX2 gene.
Alterations of LHX2 expression were previously found
in all supratentorial or hypothalamo-chiasmatic region
Fig. 3 Results of analysis of correlation between gene expression profile and location of childhood pilocytic astrocytomas. a results of probesets
expression according to clinical subgroup. b unsupervised hierarchical clustering demonstrated that PA from the three main locations have a
unique transcriptome profile. c anatomical location-related subgroups are clearly distinct in fully unsupervised multidimensional scaling analysis.
d Venn diagram showing numbers of location-related probesets. M1, cerebral hemispheric tumor; M2, optic tract and hypothalamic tumor; M3,
cerebellar tumor; M3R1, cystic cerebellar tumor with an non-enhanced cyst; M3R2, cystic cerebellar tumor with enhanced cyst; M3R3, solid cerebellar
tumor with central necrosis; M3R4, solid or mainly solid cerebellar tumor; NF1, tumor linked to the neurofibromatosis type 1; P2, progressive tumor
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tumors [8, 9]. Here we confirmed significantly higher
levels of gene expression for PAs located within the
hypothalamo-chiasmatic region. The validation of array
data reached statistical significance and allowed us to
distinguish these two subgroups of supratentorial tu-
mors on the basis of LHX2 activity. The LHX2 gene has
a known function in brain development during embryo-
genesis among different organisms. Previous functional
studies on model organisms showed the relationship
between lhx2 and two six3 genes in forebrain develop-
ment. Recent analyses of human embryonic stem cells
demonstrated that it also has a crucial role in human
brain morphogenesis [27, 28]. There is evidence that
LHX2 is expressed in the early neural lineage, which af-
fects signaling pathways fundamental for early lineage
differentiation in the human brain via regulation of the
neural transcription factors from the SIX gene family
[28, 29]. Our results constitute confirmation of this
observation. The unique transcriptional profile of our
hypothalamo-chiasmatic region tumors was character-
ized by the overrepresentation of several SIX homeobox
transcription factors, SIX1, SIX3 and SIX6.
The upregulation of other homeobox transcription fac-
tors was also observed by us in cases of infratentorial
tumor, which was shown to be connected with Iroquois
homeobox transcription factors (IRX1, IRX2, IRX3,
IRX5) and the PAX3 gene. A similar trend was noted by
Sharma et al. [9]. These genes play a crucial role in early
brain regionalization, including patterning of the
anterior-posterior and dorso-ventral axis, as well as the
differentiation of its specific regions. On model organisms
its homologs overexpression induces the occurrence of
ectopic neural tissue and causes inhibition of neuronal dif-
ferentiation [30, 31].
Contactin family genes (CNTN1, CNTN3), which func-
tion as cell adhesion molecules with an essential role in
later stages of cerebellar morphogenesis and differenti-
ation, were also significantly overrepresentated in our
cohort of cerebellar tumors [32, 33]. Moreover, recent
experimental analysis of developing mice cerebellum
suggests the cooperation of CNTN proteins in modulat-
ing SHH-induced neuronal precursor proliferation and
its connection with foliation of the cerebellum [32]. The
deregulation of the SHH signaling pathway in cerebellar
granule neuron precursors is one of the crucial causes of
the SHH subgroup of medulloblastoma, but recent ob-
servations also associate this signaling pathway with
other central nervous system tumors, including gliomas
[34]. This is the first report where CNTN1 and CNTN3
gene expression were shown to be connected with cere-
bellar pilocytic astrocytomas biology. Also our following
observation concerning misregulation of miR-324-5p,
engaged in the tumorigenesis of various cancers includ-
ing glial tumors, suggests SHH contribution in PA biol-
ogy as probably the consequence of changed progenitor
differentiation [35–37].
Another interesting finding concerns the RUNX1T1
transcript upregulation observed in silico study per-
formed for pilocytic astrocytomas by Deshmukh et al.
On the basis of the transcriptional regulatory network,
Fig. 4 Results of association of radiological features with global gene expression profile. a probesets expression showing a relatively small amplitude
of differences radiological subgroups. b unsupervised hierarchical clustering did not show specific gene expression signature correlated with
radiological features (32 probesets, FDR adjusted p < 0.005). c radiological-related subgroups are not distinct in fully unsupervised multidimensional
scaling analysis. R1, cystic tumor without an enhanced cyst wall; R2, cystic tumor with enhanced cyst; R3, solid tumor with central necrosis; R4, solid or
mainly solid tumor
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they indicated that RUNX1T1, together with four other
transcription factors, is within alteration common for
pilocytic astrocytomas and glioblastomas [38]. This is
not the only relationship between those histologically
different glial tumors. Our group of cerebellar PAs was
also characterized by elevated levels of PROM1 expres-
sion, which in glioblastoma is considered as a molecular
factor of poor prognosis, and in proneural glioblastoma
seems to be the potential target of anti-angiogenic therapy
[5, 39]. One could consider such observations as the
molecular explanation of poor outcomes observed in
some cases of PAs, but in light of findings showing gene
expression also in normal adult brain astrocytes, such
connection should be rather be regarded as additional
indication of a gene with a nearly unknown function.
Aggressive clinical behavior is more frequently observed
in pilocytic astrocytoma located within the hypothalamo-
chiasmatic region, and up to now is regarded as the result
of limited surgical excision. However, the relation of an
unfavorable disease outcome and overexpression of genes
contributes to cell growth, proliferation, and differenti-
ation, and hence it could not be excluded that it also pro-
motes the cancerogenesis and tumor metastasis observed
in PAs [40–43]. On the other hand, the frequently ob-
served (in our study) alteration of genes involved in brain
structures’ development like homeobox transcription fac-
tors, contactins and miRNAs inducing neurogenesis,
together with the generally benign behavior of PAs, lead
to the statement that these tumors could be rather recog-
nized by some scientists as a neurodevelopmental disorder
[7, 27, 28, 32, 44]. Another argument for this is the coex-
istence of neurodevelopmental disorders and pilocytic
















228462_at IRX2 Iroquois homeobox 2 <1e-07 <1e-07 7.81 36.27 470.74 (1, 2), (1, 3), (2, 3)
231666_at PAX3 Paired box 3 <1e-07 <1e-07 4.97 7.59 279.28 (1, 3), (2, 3)
207250_at SIX6 SIX homeobox 6 <1e-07 <1e-07 7.32 246.4 4.75 (1, 2), (3, 2)
206140_at LHX2 LIM homeobox 2 <1e-07 <1e-07 1680.77 2642.73 11.02 (3, 1), (3, 2)
223582_at GPR98 G protein-coupled
receptor 98
<1e-07 <1e-07 50.94 146.32 15.08 (1, 2), (3, 1), (3, 2)
230720_at RNF182 Ring finger protein 182 <1e-07 <1e-07 171.48 1797.68 2061.29 (1, 2), (1, 3)
210239_at IRX5 Iroquois homeobox 5 <1e-07 <1e-07 7.84 25.89 100.36 (1, 2), (1, 3), (2, 3)
213285_at TMEM30B Transmembrane protein 30B <1e-07 <1e-07 7.23 26.44 5.08 (1, 2), (3, 2)
230472_at IRX1 Iroquois homeobox 1 <1e-07 <1e-07 10.8 66.79 205.19 (1, 2), (1, 3), (2, 3)
227202_at CNTN1 Contactin 1 <1e-07 <1e-07 262.72 51.46 1717.72 (2, 1), (1, 3), (2, 3)
214954_at SUSD5 Sushi domain containing 5 <1e-07 <1e-07 125.14 1108.04 1603.52 (1, 2), (1, 3)
206018_at FOXG1 Forkhead box G1 <1e-07 <1e-07 1197.42 11.25 4.93 (2, 1), (3, 1)
208221_s_at SLIT1 Slit homolog 1 (Drosophila) <1e-07 <1e-07 8.42 17.8 6 (1, 2), (3, 2)
238021_s_at CRNDE Colorectal neoplasia differentially
expressed (non-protein coding)
<1e-07 <1e-07 51.09 382.35 1216.52 (1, 2), (1, 3), (2, 3)
226448_at FAM89A Family with sequence
similarity 89, member A
<1e-07 <1e-07 104 625.78 808.9 (1, 2), (1, 3)
229831_at CNTN3 Contactin 3 (plasmacytoma
associated)
<1e-07 <1e-07 21.57 9.97 176.8 (1, 3), (2, 3)
228347_at SIX1 SIX homeobox 1 <1e-07 <1e-07 13.8 421.71 9.17 (1, 2), (3, 2)
206634_at SIX3 SIX homeobox 3 <1e-07 <1e-07 4.86 49.47 4.75 (1, 2), (3, 2)
238022_at CRNDE Colorectal neoplasia
differentially expressed
(non-protein coding)
<1e-07 <1e-07 14 51.83 134.25 (1, 2), (1, 3), (2, 3)
238878_at ARX Aristaless related homeobox <1e-07 <1e-07 102.99 6.88 4.85 (2, 1), (3, 1)
227614_at HKDC1 Hexokinase domain containing 1 <1e-07 <1e-07 30.54 9.56 8.08 (2, 1), (3, 1)
205858_at NGFR Nerve growth factor receptor
(TNFR superfamily, member 16)
<1e-07 <1e-07 135.44 53.07 14.67 (3, 1), (3, 2)
M1-cerebral hemispheric tumor; M2-optic tract and hypothalamic tumor; M3-cerebellar tumor
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astrocytomas [45–47]. Such observations, which suggest
the plausible association of autism and cerebellar PAs, also
raise the question of their similar genetic background.
Until the problem of the biological characteristics of
pilocytic astrocytoma will be solved, and the degree of
surgical resection remains the only clinically confirmed
factor affecting recurrence or dissemination, there is still
a need to identify the molecular markers influencing the
clinical behavior of this tumor. Taking this into account,
we tried to search how gene expression profiling is cor-
related with the clinical outcomes of children with PA.
An additional incentive for us to perform such analyses
was the limited studies on this subject [48–50]. Unfortu-
nately in our study we didn’t observe a correlation
between a tumor’s global gene expression profile and the
clinical course of the disease. In the analysis of the uni-
variate test of progressive and low-risk disease, only five
genes differentiated between the subgroups with pro-
gressive disease and the others, but in the global test
there were no real differences between the analyzed
classes.
Hence our unsupervised analysis didn’t disclose any
differences between PA of different outcomes. The
problem with revealing genes connected with the pro-
gressive disease during expression analyses was also
noted in other studies, where such correlation were
excluded or postulated only for an extremely limited
number of genes. Sharma et al. and Rodriguez et al.
assumed that the MATN2 and ALDH1L1 genes are
connected with the progression of PA, but it seems to be
more an accidental occurrence than crucial molecular
changes. This observation was confirmed in the following
studies [9, 10]. In our opinion this could be an effect of
the low biological aggressiveness of Pas, and finding mo-
lecular factors usable in clinical practice seems very
unlikely. Moreover, malignant transformation of PAs is
really a very rare phenomenon and possible histological
misdiagnosis cannot be excluded.
We also tried to find any correlations between mo-
lecular profile and radiological features, a subject
which was completely unknown for PAs. Such plaus-
ible connections were noted in other glial brain tu-
mors such as glioblastoma and oligodendroglioma,
but this was the first attempt to find them for PAs
[8, 9, 51, 52]. Major attention was directed on tumor
borders and enhancement patterns after contrast ad-
ministration. Here we adapted the division of pre-
dominant imaging patterns of pilocytic astrocytoma
first proposed by Pencalet et al. and modified by
others [15, 16]. In our study radiological features pre-
sented by pilocytic astrocytoma were not associated
with global gene expression profile. In the univariate
test only four genes were differentiated between the
subgroups, with no differences observed in the global
test. Moreover, the genes which best discriminated be-
tween different radiological features of tumors had a
relatively small amplitude of differences and were not
good discriminators between the groups in clustering
(Fig. 4). Previous studies indicated that radiological
appearance could be a derivative of tumor location;
solid tumors were frequently observed infratentorially,
and optic tract tumors rarely consist of cystic elements
[14–16, 53]. Therefore we performed additional ana-
lyses for a cohesive subgroup of infratentorial lesions,
which also didn’t reveal any correlations. Similarly, ana-
lysis of two subgroups of tumors with mainly solid and
mostly cystic features showed no associations with
transcriptional pattern. Our results show that different
radiological patterns of PA are not determined by tran-
criptional changes.
Fig. 5 Progression of the disease was not associated with global gene expression profile. a only five genes were down regulated in group of
tumors without progression (p < 0.005). b clinical course of the disease was not distinct in fully unsupervised multidimensional scaling analysis. P1,
favorable outcome; P2, progressive disease
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Conclusions
In our comprehensive study we showed the differences
between pilocytic astrocytoma of different locations
and pointed out the heterogeneity of a tumor coming
from the supratentorial region (Table 5). We may state
that gene expression profile in pilocytic astrocytomas
is connected only with tumor location, which suggests
a different origin of PA arising within various anatom-
ical brain structures. This observation is complemen-
tary to current knowledge of pilocytic astrocytoma’s
biology and indicates that for targeted therapy three
molecular subgroups of the tumor must be considered,
particularly in the case of optimization of the treat-
ment of optic nerve PAs. Our observation, combined
Fig. 6 Results of microarray data validation performed by independent RT-qPCR on 39 samples, equally diversified according to the three main
locations. a-g values of PAX3, LHX2, CNCT1, CXCL14, IRX2, SIX6, SIX1 genes expression in pilocytic astrocytoma of different locations, presented as
medians with respective inter-quartile ranges. h p-values obtained for site-specific subgroups compared using the Kruskal-Wallis test with post hoc
pairwise comparisons using Dwass-Steel-Critchlow-Fligner test. Statistical significance was assumed as p ≤ 0.05. M1, cerebral hemispheric tumor
(13 cases); M2, optic tract and hypothalamic tumor (13 cases); M3, cerebellar tumor (13 cases)
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with the similar results of a recent methylation study
performed by Lambert et al., suggests that the molecu-
lar variation of PAs is probably the consequence of
region-specific cells of origin’s presence, as is sug-
gested in other brain tumors [54]. We pointed out the
difficulties with finding the molecular alterations con-
nected with worse clinical course of the disease, and
found no connection between radiological features and
global gene expression.
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